drugset / Trial / NCT03162926
A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this trial is to test if VC-02™ combination product can be implanted subcutaneously in subjects with Type 1 Diabetes and maintained safely for up to four (4) months.
Timeline
- Start
- 2017-07-05
- Primary completion
- 2018-02-15
- Completion
- 2018-02-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VC-02 | Cell therapy | — | Subcutaneous |